✦ LIBER ✦

Erratum to: “Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain” [PAIN® 2013;154(10):1910–19]

✍ Scribed by Sanga, Panna; Katz, Nathaniel; Polverejan, Elena; Wang, Steven; Kelly, Kathleen M.; Haeussler, Juergen; Thipphawong, John

Book ID: 122255980
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 96 KB
Volume: 155
Category: Article
ISSN: 0304-3959
DOI: 10.1016/j.pain.2013.10.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, safety, and tolerability of fu

Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in treatment of patients with moderate-to-severe osteoarthritis pain

✍ P. Sanga; N. Katz; E. Polverejan; S. Wang; K. Kelly; C. Oh; J. Thipphawong 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 36 KB

Efficacy, safety, and tolerability of fu

Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain

✍ Sanga, Panna; Katz, Nathaniel; Polverejan, Elena; Wang, Steven; Kelly, Kathleen 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 988 KB

Nerve growth factor (NGF) is increased in chronic pain conditions. This study examined analgesic efficacy and safety of fulranumab, a fully human monoclonal anti-NGF antibody, in adults with chronic osteoarthritis pain. Patients (n=466, intent-to-treat) were randomized to receive, in addition to the